drugset / Trial / NCT03612219
Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma
Phase 2
Unknown
240 enrolled
Wei Jiang
Guangxi Minzu Hospital · collabGuangxi Naxishan Hospital · collabLaibin People's Hospital · collabPeople's Hospital of Baise · collabPeople's Hospital of Lingshan · collabWuzhou Red Cross Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is to evaluate the efficacy and safety of apatinib for adjuvant treatment of High-risk metastasis of nasopharyngeal carcinoma after IMRT with concurrent chemotherapy,including progression-free survival (PFS),evaluation of drug safety.,and overall survival (OS),distant metastasisfree survival (DMFS),locoregional relapse-free survival (LRRFS),and quality of life score (QoL).
Timeline
- Start
- 2018-07-01
- Primary completion
- 2021-07-28
- Completion
- 2021-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |